A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Trade Near Recent Levels
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
ACADIA Pharmaceuticals (ACAD) has drawn fresh attention after recent trading, with the share price around $22.20 and mixed returns across different periods, including a slight month pullback and a negative move over the past 3 months.
See our latest analysis for ACADIA Pharmaceuticals.
At the current share price of $22.20, ACADIA Pharmaceuticals has seen short term share price momentum fade compared to earlier in the year, while the 1 year total shareholder return of 44.34% signals that longer term holders have fared better.
If ACADIA’s recent moves in neurological and rare disease treatments have caught your eye, it could be worth broadening your search with other specialised healthcare names through 36 healthcare AI stocks
With ACADIA trading around $22.20, showing 1-year returns of 44.34% and its recent revenue and net income figures on the table, the key question is whether there is still a buying opportunity or if markets are already pricing in future growth.
With ACADIA Pharmaceuticals last closing at $22.20 and the widely followed narrative pointing to a fair value of $28.75, the gap between price and story is clear and measurable.
ACADIA Pharmaceuticals (NASDAQ: ACAD) occupies a narrow but important corner of the healthcare market. Unlike large-cap drugmakers that pursue blockbuster indications, ACADIA focuses on highly specialized neurological and psychiatric conditions, areas where unmet need is significant and treatment options are limited.
Curious what justifies a higher fair value than today’s price? According to yiannisz, the narrative focuses on revenue expansion, rising margins, and a profitability profile more in line with mature specialty pharma than early stage biotech.
Result: Fair Value of $28.75 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this story can change quickly if key clinical trials disappoint or if reimbursement decisions limit uptake of therapies such as NUPLAZID or DAYBUE.
Find out about the key risks to this ACADIA Pharmaceuticals narrative.
If this mix of optimism and caution resonates with you, do not wait to review the full picture and weigh it against your own expectations, starting with 4 key rewards.
If ACADIA is on your radar, do not stop here. Broaden your watchlist now so you do not miss other opportunities that fit your style.
